Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by China Medical University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01255267
First received: December 6, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

In this study, we evaluate the acute coronary syndrome patients to see if there is correlation between platelet activity, genetic polymorphism (CYP2C19 and ABCB1), serum adipokines level, and Clopidogrel responsiveness.


Condition
Acute Coronary Syndrome
Chronic Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Correlation Between Genetic Polymorphism, Platelet Activity, , Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Groups/Cohorts
Acute coronary syndrome patients
Chronic coronary artery disease patients
Healthy control

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Acute coronary syndrome and chronic coronary artery diseae patients

Criteria

Inclusion Criteria:

  1. Age > 18 y/o
  2. Acute coronary syndrome patients
  3. Chronic coronary artery disease patients
  4. Healthy volunteers

Exclusion Criteria:

  1. Patient refusal
  2. Allergy to Clopidogrel
  3. Receive Gp IIb/IIIa inhibitor simultaneously
  4. Cancer history
  5. Severe renal and liver function impairment
  6. Coagulopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01255267

Contacts
Contact: Yu-Chen Wang, MD 886-4-22052121 ext 2371 richard9250@yahoo.com.tw

Locations
Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan
Contact: Yu-Chen Wang, MD    886-4-22052121 ext 2371    richard9250@yahoo.com.tw   
Sponsors and Collaborators
China Medical University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01255267     History of Changes
Other Study ID Numbers: DMR99-IRB-041
Study First Received: December 6, 2010
Last Updated: December 6, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by China Medical University Hospital:
Acute coronary syndrome and chronic coronary artery disease patients

Additional relevant MeSH terms:
Acute Coronary Syndrome
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Syndrome
Angina Pectoris
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Chest Pain
Disease
Heart Diseases
Pain
Pathologic Processes
Signs and Symptoms
Vascular Diseases
Clopidogrel
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014